[Treatment of non-small-cell lung cancer by dual (bronchial and pulmonary) arterial drug infusion].
Since the lung receives blood supply from both the bronchial and pulmonary arteries, chemotherapeutic agents given through both channels would give higher local drug concentration and better therapeutic results in the treatment of lung cancer. In this study, 10 patients with advanced NSCLC were treated by dual arterial infusion (DAI) of carboplatin (300mg/m2) and VP-16 (200-300mg/m2) twice at 3-week interval. From DAI treatment, a response rate of 80% (CR 2, PR 6) was achieved. In 5 patients DAI treatment had made surgical resection of the lung cancer possible. The 1-, 2- and 3-year survivors were 8, 6 and 5 respectively, with a median survival time of 11.5 months.
Shi
W
W
Department of Thoracic Surgery, 2nd Affiliated Hospital China Medical University, Shenyang.
Zhang
S
S
Zhang
X
X
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001981:Bronchial Arteries; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality; D002945:Cisplatin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007261:Infusions, Intra-Arterial / Q000379:methods; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D011651:Pulmonary Artery; D015996:Survival Rate
D005047:Etoposide; D002945:Cisplatin